Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients

Japanese Journal of Clinical Oncology

Volumn 36, Issue 3, 2006, Pages 150-153

  Kurebayashi, Junichi ^a   Nomura, Tsunehisa ^a   Hirono, Mai ^a   Okubo, Sumiko ^a   Udagawa, Kiyoshi ^a   Shiiki, Shigeo ^a   Ikeda, Masahiko ^a   Nakashima, Kazutaka ^a   Tanaka, Katsuhiro ^a   Sonoo, Hiroshi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Breast cancer; CA15 3; CEA; CSLEX; Metastasis

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; SIALYL LEWIS X ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANALYTICAL PARAMETERS; ANTIGEN DETECTION; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PATIENT MONITORING; POSTOPERATIVE PERIOD; PREDICTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RELIABILITY; SENSITIVITY AND SPECIFICITY; SOFT TISSUE METASTASIS; VISCERAL METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; OLIGOSACCHARIDES; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33645885301     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi235     Document Type: Article

References (15)

1. Kurebayashi J, Yamamoto Y, Tanaka K, Ogawa Y, Kurosumi M, Kohno N, et al. Current status of tumor markers of breast cancer in Japan: A questionanaire survey to the board members of the Japanese Breast Cancer Society. Jpn J Breast Cancer 2002;17:165-9 (in Japanese with English Abstract).
2. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, et al. American Society of Clinical Oncology Tumor Markers Expert Panel: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
3. Robertson JF, Whynes DK, Dixon A, Blamey RW. Potential for cost economies in guiding therapy in patients with metastatic breast cancer. Br J Cancer 1995;72:174-7.
4. Kurebayashi J, Yamamoto Y, Tanaka K, Kohno N, Kurosumi M, Moriya T, et al. Significance of serum carcinoembryonic antigen and CA15-3 in monitoring advanced breast cancer patients treated with systemic therapy: A large-scale retrospective study. Breast Cancer 2003;10:38-44.
5. Kurebayashi J, Nishimura R, Tanaka K, Kohno N, Kurosumi M, Moriya T, et al. Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: A prospective study. Breast Cancer 2004;11:389-95.
6. Safi F, Kohler I, Rottinger E, Suhr P, Beger HG. Comparison of CA15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 1989;4:207-14.
7. Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: A prospective longitudinal study. Clin Cancer Res 2001;7:2357-62.
8. Lamerz R, Stieber P, Fateh-Moghadam A. Serum marker combinations in human breast cancer (review). In Vivo 1993;7:607-13.
9. Martoni A, Zamagni C, Bellanova B, Zanichelli L, Vecchi F, Cacciari N, et al. CEA, MCA, CA15.3 and CA549 and their combinations in expressing and monitoring metastatic breast cancer: A prospective comparative study. Eur J Cancer 1995;31A:1615-21.
10. D'Alessandro R, Roselli M, Ferroni P, Mariotti S, Spila A, Aloe S, et al. Serum tissue polypeptide specific antigen (TPS): A complementary tumor marker to CA15-3 in the management of breast cancer. Breast Cancer Res Treat 2001;68:9-19.
11. Fukushima K, Hirota M, Terasaki PI, Wakisaka A, Togashi H, Chia D, et al. Characterization of sialosylated Lewisx as a new tumor-associated antigen. Cancer Res 1984;44:5279-85.
12. Satoh H, Ishikawa H, Kamma H, Yamashita YT, Takahashi H, Ohtsuka M, et al. Serum sialyl lewis X-i antigen levels in non-small cell lung cancer: correlation with distant metastasis and survival. Clin Cancer Res 1997;3:495-9.
13. Futamura N, Nakamura S, Tatematsu M, Yamamura Y, Kannagi R, Hirose H. Clinicopathologic significance of sialyl Le(x) expression in advanced gastric carcinoma. Br J Cancer 2000;83:1681-7.
14. Sato T, Nishimura G, Nonomura A, Miwa K, Miyaz I. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer. Hepatogastroenterology 1999;46:914-9.
15. Matsuura N, Narita T, Mitsuoka C, Kimura N, Kannagi R, Imai T, et al. Increased level of circulating adhesion molecules in the sera of breast cancer patients with distant metastases. Jpn J Clin Oncol 1997;27: 135-9.